EP3222619A1
(de)
|
1999-04-15 |
2017-09-27 |
Bristol-Myers Squibb Holdings Ireland |
Cyclische proteintyrosinkinase-inhibitoren
|
PT1347971E
(pt)
|
2000-12-21 |
2006-06-30 |
Bristol Myers Squibb Co |
Inibidores tiazolilicos de tirosina-cinases da familia tec
|
EP1671969A3
(de)
*
|
2000-12-21 |
2006-07-26 |
Bristol-Myers Squibb Company |
Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
|
DE122010000038I1
(de)
|
2000-12-21 |
2011-01-27 |
Glaxosmithkline Llc |
Pyrimidinamine als angiogenesemodulatoren
|
US20040102455A1
(en)
*
|
2001-01-30 |
2004-05-27 |
Burns Christopher John |
Method of inhibiting kinases
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
EP1392300A1
(de)
|
2001-05-11 |
2004-03-03 |
Vertex Pharmaceuticals Incorporated |
2,5-disubstituierte pyridin, pyrimid, pyridazin und 1,2,4-triazin derivate zur verwendung als p38 inhibitoren
|
US7087614B2
(en)
|
2001-06-19 |
2006-08-08 |
Bristol-Myers Squibb Co. |
Pyrimidine inhibitors of phosphodiesterase (PDE) 7
|
ES2255621T3
(es)
*
|
2001-06-22 |
2006-07-01 |
MERCK & CO., INC. |
Inhibidores de tirosina quinasa.
|
DE10133665A1
(de)
*
|
2001-07-11 |
2003-01-30 |
Boehringer Ingelheim Pharma |
Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
|
WO2003015778A1
(en)
|
2001-08-17 |
2003-02-27 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US20030211040A1
(en)
|
2001-08-31 |
2003-11-13 |
Paul Greengard |
Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
|
WO2003027320A2
(en)
*
|
2001-09-24 |
2003-04-03 |
University Of Aarhus |
Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
|
WO2003062215A1
(en)
*
|
2002-01-25 |
2003-07-31 |
Kylix Pharmaceuticals B.V. |
4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
|
US20040014744A1
(en)
*
|
2002-04-05 |
2004-01-22 |
Fortuna Haviv |
Substituted pyridines having antiangiogenic activity
|
US7125888B2
(en)
|
2002-05-02 |
2006-10-24 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
DE60317198T2
(de)
*
|
2002-05-23 |
2008-12-04 |
Cytopia Research Pty. Ltd., Richmond |
Proteinkinaseinhibitoren
|
US20040023981A1
(en)
*
|
2002-07-24 |
2004-02-05 |
Yu Ren |
Salt forms with tyrosine kinase activity
|
US20040023978A1
(en)
*
|
2002-07-24 |
2004-02-05 |
Yu Ren |
Active salt forms with tyrosine kinase activity
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
NZ540161A
(en)
*
|
2002-10-30 |
2008-03-28 |
Vertex Pharma |
Compositions useful as inhibitors of rock and other protein kinases
|
AU2002953255A0
(en)
*
|
2002-12-11 |
2003-01-02 |
Cytopia Research Pty Ltd |
Protein kinase inhibitors
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
GB2400101A
(en)
*
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
AR044519A1
(es)
*
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
|
WO2005000208A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Combinatorx, Inc. |
Combination therapy for the treatment of neoplasms
|
EP1644365A2
(de)
*
|
2003-07-02 |
2006-04-12 |
Biofocus Discovery Ltd |
Pyrazin- und pyridinderivative als rho-kinase-inhibitoren
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
GB0320197D0
(en)
|
2003-08-28 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
CA2857067C
(en)
|
2003-12-03 |
2016-11-22 |
Ym Biosciences Australia Pty Ltd |
Tubulin inhibitors
|
US7294640B2
(en)
|
2004-02-06 |
2007-11-13 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
WO2006008874A1
(ja)
*
|
2004-05-21 |
2006-01-26 |
Banyu Pharmaceutical Co., Ltd. |
アミノチアゾール骨格を有するCdk4,6選択的阻害剤
|
ATE415397T1
(de)
*
|
2004-06-04 |
2008-12-15 |
Arena Pharm Inc |
Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
|
WO2006046735A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Banyu Pharmaceutical Co., Ltd. |
Novel aminopyridine derivatives having aurora a selective inhibitory action
|
US7491720B2
(en)
|
2004-10-29 |
2009-02-17 |
Banyu Pharmaceutical Co., Ltd. |
Aminopyridine derivatives having Aurora A selective inhibitory action
|
JP2008519814A
(ja)
*
|
2004-11-12 |
2008-06-12 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物
|
GB0428082D0
(en)
|
2004-12-22 |
2005-01-26 |
Welcome Trust The Ltd |
Therapeutic compounds
|
HUE025671T2
(en)
|
2005-02-04 |
2016-04-28 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
JP5001179B2
(ja)
|
2005-02-16 |
2012-08-15 |
アストラゼネカ アクチボラグ |
化学物質
|
EP1899323A2
(de)
|
2005-05-16 |
2008-03-19 |
AstraZeneca AB |
Als tyrosinkinaseinhibitoren geeignete pyrazolylaminopyrimidinderivate
|
CN101304995B
(zh)
*
|
2005-05-24 |
2011-10-19 |
默克雪兰诺有限公司 |
噻唑衍生物及其应用
|
WO2006129842A1
(ja)
*
|
2005-06-01 |
2006-12-07 |
Banyu Pharmaceutical Co., Ltd. |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
AU2006255028B2
(en)
|
2005-06-06 |
2012-04-19 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
AU2006258101A1
(en)
*
|
2005-06-09 |
2006-12-21 |
Merck Sharp & Dohme Corp. |
Inhibitors of checkpoint kinases
|
EP1912959A2
(de)
*
|
2005-08-02 |
2008-04-23 |
Irm Llc |
5-substituierte thiazol-2-ylaminoverbindungen und zusammensetzungen als proteinkinaseinhibitoren
|
US20080194592A1
(en)
*
|
2005-08-23 |
2008-08-14 |
Intra-Cellular Therapies, Inc. |
Organic Compounds
|
DK1945631T3
(da)
|
2005-10-28 |
2012-10-22 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
|
EP1948652B1
(de)
*
|
2005-11-01 |
2011-08-24 |
Array Biopharma, Inc. |
Glucokinaseaktivatoren
|
US20070130203A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Ask Jeeves, Inc. |
Method and system to provide targeted advertising with search results
|
KR100728221B1
(ko)
*
|
2005-12-08 |
2007-06-13 |
한국전자통신연구원 |
터보부호 ofdm 시스템용 반복적 잔류 주파수 위상 보정장치 및 그 방법
|
US7572809B2
(en)
*
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
CA2637172A1
(en)
*
|
2006-01-27 |
2007-08-09 |
Array Biopharma Inc. |
Pyridin-2-amine derivatives and their use as glucokinase activators
|
WO2007097839A2
(en)
*
|
2006-02-16 |
2007-08-30 |
Massachusetts Eye And Ear Infirmary |
Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
|
TWI393718B
(zh)
|
2006-03-24 |
2013-04-21 |
Array Biopharma Inc |
葡萄糖激酶活化劑
|
US7998978B2
(en)
|
2006-05-01 |
2011-08-16 |
Pfizer Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
US8246966B2
(en)
*
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
JP2008081492A
(ja)
*
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
EP2081431B1
(de)
|
2006-11-13 |
2013-01-16 |
Intra-Cellular Therapies, Inc. |
Organische verbindungen
|
EP2088863A2
(de)
|
2006-11-22 |
2009-08-19 |
University Of Georgia Research Foundation, Inc. |
Tyrosinkinase-hemmer als antikinetolastid- und anti-sporentierchen-wirkstoffe
|
US9006258B2
(en)
|
2006-12-05 |
2015-04-14 |
Intra-Cellular Therapies, Inc. |
Method of treating female sexual dysfunction with a PDE1 inhibitor
|
EP2118088B1
(de)
|
2006-12-20 |
2012-05-30 |
Amgen Inc. |
Heterocyclische Verbindungen und ihre Verwendung bei der Behandlung von Entzündungen, Angiogenese und Krebs
|
MX2009008665A
(es)
*
|
2007-02-13 |
2009-08-21 |
Ab Science |
Procedimiento para la sintesis de compuestos de 2-aminotiazol como inhibidores de quinasa.
|
US20100104567A1
(en)
|
2007-03-05 |
2010-04-29 |
Kyowa Hakko Kirin Co., Ltd. |
Pharmaceutical composition
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
AU2008305294B2
(en)
|
2007-09-21 |
2012-11-29 |
Array Biopharma Inc. |
Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
|
ES2399469T3
(es)
|
2007-10-09 |
2013-04-01 |
Merck Patent Gmbh |
Derivados de la piridina útiles como activadores de la glucoquinasa
|
CN101952282A
(zh)
|
2007-12-20 |
2011-01-19 |
诺瓦提斯公司 |
用作pi 3激酶抑制剂的噻唑衍生物
|
JPWO2009130900A1
(ja)
*
|
2008-04-24 |
2011-08-11 |
日本曹達株式会社 |
オキシム誘導体、中間体化合物および植物病害防除剤
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
US11464781B2
(en)
|
2009-02-25 |
2022-10-11 |
Intra-Cellular Therapies, Inc. |
PDE1 inhibitors for ophthalmic disorders
|
EP2434895A4
(de)
|
2009-05-13 |
2013-08-07 |
Intra Cellular Therapies Inc |
Organische verbindungen
|
US8293753B2
(en)
*
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
JP5589077B2
(ja)
|
2009-07-20 |
2014-09-10 |
ブリストル−マイヤーズ スクイブ カンパニー |
増殖性疾患の相乗的処置のための抗ctla4抗体と多様な治療レジメンとの組み合わせ
|
SG178279A1
(en)
|
2009-08-05 |
2012-03-29 |
Intra Cellular Therapies Inc |
Novel regulatory proteins and inhibitors
|
US8653146B2
(en)
|
2009-08-31 |
2014-02-18 |
Postech Academy-Industry Foundation |
Method for treating Th17 inflammatory disease through inhibition of vascular endothelial growth factor receptors and pharmaceutical composition therefor
|
NZ599460A
(en)
|
2009-10-20 |
2014-07-25 |
Nestec Sa |
Proximity-mediated assays for detecting oncogenic fusion proteins
|
KR100953511B1
(ko)
*
|
2009-12-28 |
2010-04-21 |
(주)지노믹트리 |
건선 진단용 키트 및 칩
|
CA2784807C
(en)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
WO2012080284A2
(en)
|
2010-12-17 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
|
AU2012254154B2
(en)
|
2011-02-17 |
2015-11-05 |
Société des Produits Nestlé S.A. |
Apparatus and method for isolating leukocytes and tumor cells by filtration
|
UA112539C2
(uk)
|
2011-03-03 |
2016-09-26 |
Новартіс Аг |
Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
|
US9255072B2
(en)
*
|
2011-03-04 |
2016-02-09 |
National Health Rsearch Institutes |
Pyrazole compounds and thiazole compounds as protein kinases inhibitors
|
RU2011122942A
(ru)
*
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
CA2846347C
(en)
|
2011-09-12 |
2019-05-21 |
Sanofi |
Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
|
US8912224B2
(en)
|
2011-09-12 |
2014-12-16 |
Sanofi |
Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
|
PL2567958T3
(pl)
|
2011-09-12 |
2015-04-30 |
Sanofi Sa |
Podstawione 2-(chroman-6-yloksy)-tiazole i ich zastosowanie jako środków leczniczych
|
MX359257B
(es)
|
2012-05-04 |
2018-09-19 |
Pfizer |
Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
|
AU2013268400B2
(en)
*
|
2012-05-30 |
2017-07-13 |
Nippon Shinyaku Co., Ltd. |
Aromatic heterocyclic derivative and pharmaceutical
|
US9801882B2
(en)
|
2013-02-17 |
2017-10-31 |
Intra-Cellular Therapies, Inc. |
Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
|
EP2970279B1
(de)
|
2013-03-15 |
2020-09-16 |
Intra-Cellular Therapies, Inc. |
Organische verbindungen
|
ES2871327T3
(es)
|
2013-03-15 |
2021-10-28 |
Intra Cellular Therapies Inc |
Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de enfermedades o trastornos de SNC o SNP
|
CN103254184B
(zh)
*
|
2013-05-27 |
2015-03-18 |
湖南科技大学 |
5-取代-3-[5-羟基-4-吡喃酮-2-基-甲硫基]-4-氨基-1,2,4-三唑类化合物及其用途
|
CN103319467B
(zh)
*
|
2013-06-15 |
2015-10-14 |
湖南科技大学 |
一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途
|
MX371455B
(es)
|
2013-08-02 |
2020-01-28 |
Pfizer |
Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
|
PL226024B1
(pl)
|
2013-10-23 |
2017-06-30 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną |
Zastosowanie N-[2-[4-(4-metoksyfenylo)-1,3-tiazol-2-ilo]etylo]- -2-okso-2,5,6,7-tetrahydrocyklopenta[b] pirydyno-3-karboksyamidu
|
JP6810613B2
(ja)
|
2014-06-20 |
2021-01-06 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
WO2016022893A1
(en)
|
2014-08-07 |
2016-02-11 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10059702B2
(en)
|
2014-09-08 |
2018-08-28 |
The Johns Hopkins University |
Inhibitors of LC3/ATG3 interaction and their use in the treatment of cancer
|
ES2857567T3
(es)
|
2014-09-17 |
2021-09-29 |
Intra Cellular Therapies Inc |
Derivados de 7,8-dihidro-[2h]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5h)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
|
ES2708030T3
(es)
|
2014-10-20 |
2019-04-08 |
Inst Nat Sante Rech Med |
Métodos para explorar a un individuo en busca de un cáncer
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Axlに対するヒトモノクローナル抗体
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
WO2016160617A2
(en)
|
2015-03-27 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
SI3300500T1
(sl)
|
2015-05-20 |
2020-07-31 |
Amgen Inc. |
Triazolni agonisti receptorja APJ
|
US10464896B2
(en)
|
2015-06-11 |
2019-11-05 |
Basilea Pharmaceutica International AG |
Efflux-pump inhibitors and therapeutic uses thereof
|
US20180201687A1
(en)
|
2015-07-07 |
2018-07-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to myosin 18a and uses thereof
|
EP3341732B1
(de)
|
2015-08-27 |
2023-07-12 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren zur vorhersage der überlebenszeit von patienten mit lungenkrebs
|
EP3347018B1
(de)
|
2015-09-09 |
2021-09-01 |
Dana-Farber Cancer Institute, Inc. |
Hemmer von cyclinabhängigen kinasen
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
MX2018010295A
(es)
|
2016-02-26 |
2019-06-06 |
Inst Nat Sante Rech Med |
Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
|
US10682354B2
(en)
|
2016-03-28 |
2020-06-16 |
Intra-Cellular Therapies, Inc. |
Compositions and methods
|
US9988369B2
(en)
|
2016-05-03 |
2018-06-05 |
Amgen Inc. |
Heterocyclic triazole compounds as agonists of the APJ receptor
|
KR20230003387A
(ko)
|
2016-05-25 |
2023-01-05 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 |
암 치료 방법 및 조성물
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
US11186634B2
(en)
|
2016-07-29 |
2021-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies targeting tumor associated macrophages and uses thereof
|
JP7134168B6
(ja)
|
2016-09-12 |
2024-02-02 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
SI3529262T1
(sl)
|
2016-10-21 |
2021-12-31 |
Inserm - Institut National De La Sante Et De La Recherche Medicale |
Postopki za spodbujanje odgovora T-celic
|
EP3538140A1
(de)
|
2016-11-14 |
2019-09-18 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Verfahren und pharmazeutische zusammensetzungen zur modulation von stammzellenproliferation oder -differenzierung
|
US11020395B2
(en)
|
2016-11-16 |
2021-06-01 |
Amgen Inc. |
Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
|
WO2018093576A1
(en)
|
2016-11-16 |
2018-05-24 |
Amgen Inc. |
Alkyl substituted triazole compounds as agonists of the apj receptor
|
US10736883B2
(en)
|
2016-11-16 |
2020-08-11 |
Amgen Inc. |
Triazole furan compounds as agonists of the APJ receptor
|
US10689367B2
(en)
|
2016-11-16 |
2020-06-23 |
Amgen Inc. |
Triazole pyridyl compounds as agonists of the APJ receptor
|
EP3541805B1
(de)
|
2016-11-16 |
2020-10-14 |
Amgen Inc. |
Heteroaryl-substituierte triazole als apj-rezeptoragonisten
|
EP3541810B1
(de)
|
2016-11-16 |
2020-12-23 |
Amgen Inc. |
Triazol-phenyl-verbindungen als agonisten des apj-rezeptors
|
CN110392697A
(zh)
|
2017-03-02 |
2019-10-29 |
国家医疗保健研究所 |
对nectin-4具有特异性的抗体及其用途
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
US11351136B2
(en)
*
|
2017-04-21 |
2022-06-07 |
Yamo Pharmaceuticals Llc |
Compositions and methods for treating retinopathy
|
JP7323457B2
(ja)
|
2017-05-18 |
2023-08-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
肥満細胞疾患の処置のための方法及び医薬組成物
|
WO2019072885A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
MAGNETIC NANOPARTICLES FOR THE TREATMENT OF CANCER
|
WO2019072888A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS OF PREDICTING THE THERAPEUTIC RESPONSE IN HEPATOCELLULAR CANCER
|
US11149040B2
(en)
|
2017-11-03 |
2021-10-19 |
Amgen Inc. |
Fused triazole agonists of the APJ receptor
|
WO2019101956A1
(en)
|
2017-11-24 |
2019-05-31 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Methods and compositions for treating cancers
|
EP3720974A1
(de)
|
2017-12-07 |
2020-10-14 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Verfahren zum screening eines patienten auf einen krebs
|
CN107868040A
(zh)
*
|
2017-12-21 |
2018-04-03 |
苏州艾缇克药物化学有限公司 |
一种2‑氨基吡啶‑4‑甲酸甲酯的合成方法
|
EP3746081A4
(de)
|
2018-01-31 |
2021-10-27 |
Intra-Cellular Therapies, Inc. |
Neuartige verwendungen
|
EP3775206A1
(de)
|
2018-03-28 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von krebs
|
KR102245670B1
(ko)
*
|
2018-04-03 |
2021-04-29 |
영남대학교 산학협력단 |
신규한 6-헤테로아릴아미노-2,4,5-트라이메틸피리딘-3-올 화합물, 또는 이를 포함하는 염증성 장질환 및 자가면역 질환의 예방 또는 치료용 약학 조성물
|
US20210164984A1
(en)
|
2018-04-13 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
|
MA52487A
(fr)
|
2018-05-01 |
2021-03-10 |
Amgen Inc |
Pyrimidinones substituées en tant qu'agonistes du récepteur apj
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019229115A1
(en)
|
2018-05-30 |
2019-12-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
CN112703011A
(zh)
|
2018-08-06 |
2021-04-23 |
国家医疗保健研究所 |
用于治疗癌症的方法和组合物
|
KR102328682B1
(ko)
*
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
WO2020053122A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
US20220098674A1
(en)
|
2019-02-13 |
2022-03-31 |
Inserm (Institut National De La Santé Et Dr La Recherch Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
JP2022523544A
(ja)
|
2019-03-06 |
2022-04-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Cmmrdの診断方法
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
US20220251232A1
(en)
|
2019-05-20 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel anti-cd25 antibodies
|
US20220290244A1
(en)
|
2019-08-02 |
2022-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for screening a subject for a cancer
|
JP2023509260A
(ja)
|
2019-08-14 |
2023-03-08 |
インサイト・コーポレイション |
Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物
|
EP3800201A1
(de)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h-stimulierung verbessert nk-zellen-abtötungsaktivitäten
|
CN115298177A
(zh)
|
2019-10-11 |
2022-11-04 |
因赛特公司 |
作为cdk2抑制剂的双环胺
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
JP2023525053A
(ja)
|
2020-05-12 |
2023-06-14 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
皮膚t細胞リンパ腫及びtfh由来リンパ腫を処置する新しい方法
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
JP2024508633A
(ja)
|
2021-01-29 |
2024-02-28 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
Msi癌を診断する方法
|
US20220389104A1
(en)
|
2021-05-28 |
2022-12-08 |
Ose Immunotherapeutics |
Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
|
CN114230514A
(zh)
*
|
2021-11-26 |
2022-03-25 |
渭南瑞联制药有限责任公司 |
一种合成3-氟-2-氨基异烟腈的方法
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024061930A1
(en)
|
2022-09-22 |
2024-03-28 |
Institut National de la Santé et de la Recherche Médicale |
New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
|